Evofem Biosciences

196 articles about Evofem Biosciences

• Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021

  12/9/2021

   Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021.

• Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate

  11/30/2021

  Evofem Biosciences, Inc. (NASDAQ: EVFM) today reported a successful Type C meeting with the U.S. Food and Drug Administration in which agreement was reached on the preliminary submission strategy for EVO100.

• Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023

  11/22/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has successfully extended the cumulative net sales covenant timing of its April 2020 Securities Purchase and Security Agreement to June 30, 2023 .

• Evofem Biosciences to Participate in Piper Sandler 33rd Annual Healthcare Conference

  11/19/2021

  Evofem Biosciences, Inc., today announced that Chief Executive Officer Saundra Pelletier will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 29 – December 2, 2021.

• Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update

  11/15/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine-month periods ended September 30, 2021.

• Evofem Biosciences Announces Regulatory Submission in Mexico for Its Hormone-Free Contraceptive

  11/10/2021

  Evofem Biosciences, Inc., announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS.

• Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference

  11/4/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows:

• Evofem Biosciences to Report Third Quarter 2021 Results and Provide Corporate Update on Monday, November 15, 2021

  10/28/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET ( 1:30 p.m. PT ).

• Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock

  10/12/2021

  Evofem Biosciences, Inc. announced that it has entered into a definitive agreement with Keystone Capital Partners providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share.

• Evofem Biosciences Commends House of Representatives Leaders for Action to Ensure Coverage for the Full Range of Contraceptives Under ACA

  10/8/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives  to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA).

• Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021

  9/30/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021 .

• Evofem Biosciences Announces Publication in Peer-Reviewed Journal Advances in Therapy

  9/27/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the peer-reviewed journal Advances in Therapy.

• Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator

  9/16/2021

   Evofem Biosciences, Inc., today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021 .

• Evofem Biosciences to Participate in Investor Conferences

  9/1/2021

   Evofem Biosciences, Inc., today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows: 

• Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update

  8/11/2021

  Evofem Biosciences, Inc today reported financial results for the three- and six-month periods ended June 30, 2021.

• Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021

  7/28/2021

  Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

• Evofem Biosciences to Present at Jefferies Virtual Healthcare Conference 2021

  6/1/2021

  Evofem Biosciences, Inc., (NASDAQ:  EVFM ) today announced that Saundra Pelletier , Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference 2021 as follows:

• Evofem Biosciences to Present at LD Micro Invitational XI on Tuesday, June 8, 2021

  5/25/2021

  Evofem Biosciences, Inc., announced that its CEO Saundra Pelletier will present at the 2021 LD Micro Invitational XI on Tuesday, June 8, 2021 at 1:00 p.m. ET.

• Evofem Biosciences Announces Closing of $50 Million Public Offering - May 21, 2021

  5/21/2021

  Evofem Biosciences, Inc. announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock and accompanying two-year warrants to purchase an aggregate of up to 50 million shares of common stock.

• Evofem Biosciences Announces Pricing of $50 Million Public Offering

  5/18/2021

  Company Would Receive up to an Additional $50 Million Upon Exercise of Accompanying Short-Term Warrants